Profile data is unavailable for this security.
About the company
Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. The Company’s segments include Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, Proprietary Novel Drugs, and Management Services. The Radiopharma segment comprises radiopharmaceuticals including radio pharmacies. The Contract Development and Manufacturing Organisation-Sterile Injectables segment includes contract development and manufacturing organisation-sterile injectables products. The Generics segment includes solid dosage formulations. The Contract Research, Development and Manufacturing Organisation segment includes drug discovery services, and active pharmaceutical ingredients. The Proprietary Novel Drugs segment includes patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases.
- Revenue in INR (TTM)67.03bn
- Net income in INR771.00m
- Incorporated1978
- Employees1.03k
- LocationJubilant Pharmova Ltd1A, Sector 16ANOIDA 201301IndiaIND
- Phone+91 1 204361000
- Fax+91 1 204234881
- Websitehttps://www.jubl.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shilpa Medicare Ltd | 11.51bn | 318.74m | 64.56bn | 1.03k | 179.40 | 3.17 | 46.17 | 5.61 | 3.68 | 3.68 | 134.51 | 208.37 | 0.3841 | 1.23 | 3.21 | -- | 1.07 | 2.84 | 1.41 | 3.65 | 64.63 | 61.37 | 2.78 | 7.03 | 0.7671 | 1.41 | 0.3424 | -- | 9.66 | 9.44 | 198.15 | -22.26 | -9.26 | -- |
| Blue Jet Healthcare Ltd | 7.12bn | 1.64bn | 74.42bn | -- | 45.42 | 8.80 | 38.79 | 10.46 | 9.44 | 9.44 | 41.04 | 48.73 | 0.7409 | 2.46 | 3.42 | -- | 17.05 | -- | 21.25 | -- | 55.82 | -- | 23.01 | -- | 2.80 | 1,257.13 | 0.00 | -- | -1.30 | -- | 2.33 | -- | -- | -- |
| Sun Pharma Advanced Research Co Ltd | 755.50m | -3.87bn | 81.59bn | 407.00 | -- | 64.89 | -- | 108.00 | -11.93 | -11.93 | 2.33 | 3.87 | 0.1123 | -- | 3.13 | -- | -57.57 | -61.70 | -85.93 | -119.31 | 62.77 | 76.08 | -512.52 | -163.40 | -- | -245.33 | 0.3414 | -- | -68.36 | -16.20 | -73.96 | -- | 15.40 | -- |
| F D C Ltd | 19.43bn | 3.05bn | 83.90bn | 6.37k | 27.69 | 4.00 | 24.32 | 4.32 | 18.61 | 18.61 | 118.69 | 128.81 | 0.8077 | 1.83 | 16.19 | -- | 12.68 | 12.05 | 14.56 | 13.73 | 66.23 | 62.81 | 15.70 | 15.85 | 2.18 | 74.02 | 0.0097 | -- | 8.92 | 12.24 | 57.30 | 12.45 | 16.93 | -- |
| Marksans Pharma Ltd | 21.77bn | 3.14bn | 85.19bn | 1.40k | 27.13 | 4.13 | 21.89 | 3.91 | 6.93 | 6.93 | 48.11 | 45.57 | 0.894 | 1.88 | 5.01 | -- | 12.93 | 14.62 | 15.36 | 18.52 | 52.32 | 51.22 | 14.46 | 14.03 | 3.19 | 34.30 | 0.1048 | 6.66 | 17.56 | 16.84 | 17.80 | 32.62 | 73.86 | 64.38 |
| Procter & Gamble Health Ltd | 11.69bn | 2.14bn | 85.90bn | 1.41k | 40.16 | -- | 35.68 | 7.35 | 128.85 | 128.85 | 703.49 | -- | -- | -- | -- | 8,305,331.00 | -- | -- | -- | -- | 70.45 | -- | 18.31 | -- | -- | 400.33 | -- | -- | 10.34 | -- | 19.19 | -- | -- | -- |
| Strides Pharma Science Ltd | 40.51bn | -1.25bn | 86.08bn | 2.85k | -- | 4.05 | 119.30 | 2.12 | -13.86 | -7.93 | 445.06 | 231.29 | 0.6493 | 1.44 | 3.32 | -- | -2.38 | -1.68 | -4.43 | -2.97 | 59.50 | 52.74 | -3.67 | -3.36 | 0.64 | 1.07 | 0.5485 | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
| Neuland Laboratories Ltd. | 15.59bn | 3.00bn | 99.78bn | 1.57k | 33.25 | 7.78 | 27.73 | 6.40 | 233.89 | 233.89 | 1,214.80 | 999.78 | 0.9135 | 2.33 | 4.24 | -- | 17.59 | 9.25 | 23.58 | 12.71 | 52.92 | 47.21 | 19.25 | 11.99 | 1.33 | 28.78 | 0.0692 | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
| Caplin Point Laboratories Ltd | 16.94bn | 4.57bn | 110.69bn | 777.00 | 24.31 | 4.78 | 21.50 | 6.53 | 59.90 | 59.90 | 222.01 | 304.93 | 0.6931 | 2.22 | 3.62 | -- | 18.88 | 19.83 | 21.80 | 22.82 | 57.25 | 53.99 | 27.24 | 25.39 | 4.63 | 976.47 | 0.0008 | 7.86 | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | 2.59 |
| Glenmark Life Sciences Ltd | 22.83bn | 4.71bn | 111.30bn | 1.82k | 23.67 | 4.77 | 21.23 | 4.87 | 38.38 | 38.38 | 186.08 | 190.35 | 0.8224 | 1.58 | 2.90 | -- | 16.96 | 18.28 | 20.43 | 30.03 | 56.11 | 53.40 | 20.62 | 20.23 | 2.85 | 401.55 | 0.0073 | -- | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
| Jubilant Pharmova Ltd | 67.03bn | 771.00m | 118.98bn | 1.03k | 154.93 | 2.19 | 26.17 | 1.78 | 4.85 | 4.85 | 421.25 | 343.16 | 0.5904 | 1.60 | 7.14 | -- | 0.6404 | 2.96 | 0.7627 | 3.55 | 68.06 | 69.37 | 1.08 | 5.13 | 1.37 | 2.09 | 0.4033 | 24.69 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
| Granules India Ltd | 45.06bn | 4.05bn | 127.49bn | 3.65k | 31.44 | 3.95 | 20.81 | 2.83 | 16.73 | 16.73 | 186.06 | 133.08 | 0.8645 | 1.65 | 4.66 | -- | 7.78 | 10.68 | 12.41 | 16.18 | 55.15 | 51.39 | 8.99 | 11.82 | 0.7706 | 6.13 | 0.2896 | 7.84 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
| Eris Lifesciences Ltd | 20.09bn | 3.92bn | 137.70bn | 3.55k | 35.16 | 5.32 | 23.76 | 6.85 | 28.78 | 28.78 | 147.52 | 190.12 | 0.375 | 2.37 | 5.62 | -- | 7.41 | 13.42 | 11.22 | 16.80 | 81.08 | 80.29 | 19.76 | 24.96 | 0.8345 | 5.80 | 0.4633 | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
| Wockhardt Ltd | 27.98bn | -4.63bn | 139.38bn | 2.39k | -- | 4.15 | -- | 4.98 | -32.08 | -32.08 | 194.04 | 218.97 | 0.365 | 1.80 | 3.95 | 11,687,550.00 | -6.16 | -4.56 | -11.11 | -8.29 | 58.36 | 55.26 | -16.87 | -12.70 | 0.5532 | -0.1594 | 0.3915 | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
| Sanofi India Ltd | 28.47bn | 5.49bn | 151.49bn | 2.17k | 27.59 | -- | 25.72 | 5.32 | 238.42 | 238.42 | 1,236.19 | -- | -- | -- | -- | 13,095,680.00 | -- | 22.42 | -- | 30.21 | 57.68 | 55.52 | 19.29 | 21.03 | -- | 442.82 | -- | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Astrazeneca Pharma India Ltd | 12.96bn | 1.62bn | 172.39bn | 947.00 | 106.75 | 24.22 | 97.70 | 13.31 | 64.60 | 64.60 | 518.18 | 284.77 | 1.26 | 2.84 | 9.94 | -- | 15.66 | 11.78 | 24.44 | 19.62 | 54.11 | 56.40 | 12.47 | 10.27 | 1.97 | 141.18 | 0.0064 | 27.16 | 29.17 | 12.21 | 62.66 | 24.29 | -10.45 | -- |
Data as of Jul 05 2024. Currency figures normalised to Jubilant Pharmova Ltd's reporting currency: Indian Rupee INR
19.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| East Bridge Capital Management L.P.as of 30 Sep 2023 | 11.94m | 7.50% |
| Norges Bank Investment Managementas of 30 Sep 2023 | 6.30m | 3.96% |
| The Vanguard Group, Inc.as of 06 Jun 2024 | 3.11m | 1.96% |
| quant Money Managers Ltd.as of 31 May 2024 | 3.06m | 1.92% |
| Abakkus Asset Manager LLPas of 30 Sep 2023 | 1.91m | 1.20% |
| Dimensional Fund Advisors LPas of 06 Jun 2024 | 1.66m | 1.04% |
| BlackRock Fund Advisorsas of 06 Jun 2024 | 1.09m | 0.68% |
| HBM Partners AG (Investment Management)as of 31 Mar 2024 | 835.52k | 0.53% |
| BlackRock Advisors (UK) Ltd.as of 06 Jun 2024 | 309.77k | 0.19% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 May 2024 | 217.67k | 0.14% |
More ▼
Data from 31 Dec 2023 - 15 Jun 2024Source: FactSet Research Systems Inc.
